Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ454454,80,33
KB976,1977-0,39
PKN131131,150,08
Msft77,3877,62-0,35
IBM146,51147,09-0,16
DCX68,6668,670,42
PFE35,9636,01-0,36
17.10.2017 13:23:12
Indexy online
AD Index online
select
AD Index online
 

  • 16.10.2017
Recro Pharma (NASDAQ Cons)
Závěr k 16.10.2017 Změna (%) Změna (USD) Objem obchodů (ks)
8,65 0,82 0,07 149 311
Premarket17.10.2017 13:00:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 8,10 10,49 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.10.2017
Popis společnosti
Obecné informace
Název společnostiRecro Pharma Inc
TickerREPH
Kmenové akcie:Ordinary Shares
RICREPH.O
ISINUS75629F1093
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2016 195
Akcie v oběhu k 9.8.2017 19 059 604
Počet akcionářů k 31.12.2016 9
MěnaUSD
Kontaktní informace
Ulice490 Lapp Rd
MěstoMALVERN
PSČ19355-1212
ZeměUnited States
Kontatní osobaSusan Kim
Funkce kontaktní osobyIR Contact Officer
Telefon14 843 952 400
Fax14843952471
Kontatní telefon12 126 001 902

Business Summary: Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
Financial Summary: BRIEF: For the six months ended 30 June 2017, Recro Pharma Inc revenues increased 2% to $35.7M. Net loss increased 17% to $16.9M. Revenues reflect Revenue Sales of Goods & Services increase of 2% to $34.9M. Higher net loss reflects General and administrative increase of 91% to $10.4M (expense), Change in contingent consideration valua increase of 28% to $5.8M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 17.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardWayne Weisman601.1.2008
President, Chief Executive Officer, DirectorGeraldine Henwood611.1.2008
Chief Financial OfficerMichael Celano585.7.20165.7.2016
Executive Vice President - Business DevelopmentJyrki Mattila6221.8.201721.8.2017
Senior Vice President - Finance, Chief Accounting OfficerRyan Lake395.6.20175.6.2017
Senior Vice President - Development, SecretaryRandall Mack481.1.2008
Senior Vice President - Regulatory and QualityDiane Myers511.1.2008
Chief Commercial OfficerFred Graff-16.2.201616.2.2016
Chief Medical OfficerStewart McCallum-2.12.20152.12.2015